文献速递新发突发、热带与寄生虫病

多抗原血清学与虫媒病毒感染诊断算法作为东南欧虫媒病毒防范新工具(MERMAIDS-ARBO):一项前瞻性观察研究

Multi-antigen serology and a diagnostic algorithm for the detection of arbovirus infections as novel tools for arbovirus preparedness in southeast Europe (MERMAIDS-ARBO): a prospective observational study.
PubMed 文献 · Lancet Infect Dis · 2025-02-20

863例纳入分析,确诊近期感染CCHFV 1例(<1%)、TBEV 10例(1%)、托斯卡纳病毒40例(5%)、WNV 52例(6%)。

要点

  • 602例(70%)血清采样不完整,采样时间异质,影响血清学诊断。
  • 托斯卡纳病毒确诊感染多在阿尔巴尼亚(40例中25例,63%),WNV多在罗马尼亚(52例中36例,69%)。
  • 蚊虫叮咬与WNV反应性相关(OR 2·47),蜱叮咬与TBEV反应性相关(OR 2·21)。

核心结论

  • 尽管数据不完整且异质,疑似虫媒病毒感染的鉴别诊断仍可行,所提出的诊断判读算法或可用于加强虫媒病毒病风险地区临床环境中的常规诊断。
  • 数据提示虫媒病毒监测的潜在热点及与这些特定虫媒病毒感染相关的危险因素。

研究设计与样本

  • 筛查2896人,913人符合纳入条件,其中863人(男514、女332、性别未知17)样本送至研究参考实验室并纳入分子与血清学分析。
  • 入院后第0、7、28、60天采集血清,用ELISA检测抗CCHFV IgG和IgM(间接免疫荧光试验确认),用定制蛋白微阵列检测TBEV、托斯卡纳病毒和WNV特异性IgG和IgM(病毒中和试验确认),所有急性期样本对四种病毒行PCR检测。
  • 按地区和年份对病毒反应性病例行描述性分析,并评估年龄、性别、昆虫叮咬等可能的病毒反应性相关因素。

主要发现

  • 经结合采样时间与完整性的判读表判定,确诊近期感染CCHFV 1例(<1%)、TBEV 10例(1%)、托斯卡纳病毒40例(5%)、WNV 52例(6%)。
  • 托斯卡纳病毒急性确诊病例多在阿尔巴尼亚(40例中25例,63%),WNV主要在罗马尼亚(52例中36例,69%)。
  • 阿尔巴尼亚托斯卡纳病毒总体血清阳性率最高(282例中168例,60%),主要因确诊暴露或既往暴露患者(168例中104例,62%)。
  • 无WNV或托斯卡纳病毒抗体者显著年轻于有抗体者:WNV平均差-8·48岁(95% CI -12·31至-4·64),托斯卡纳病毒-6·97岁(-9·59至-4·35)。
  • 男性托斯卡纳病毒反应性比值比升高(OR 1·56[95% CI 1·15至2·11];p=0·0055);蚊虫叮咬较无叮咬者WNV反应性OR 2·47(1·54至3·97;p=0·0002);蜱叮咬较无叮咬者TBEV反应性OR 2·21(1·19至4·11;p=0·018)。

关键数值与推荐

  • 诊断判读表结合采样时间与采样完整性判定近期感染:CCHFV 1例(<1%)、TBEV 10例(1%)、托斯卡纳病毒40例(5%)、WNV 52例(6%)。
  • 602例(70%)患者血清采样不完整(如一个或多个时间点样本缺失或症状出现时间数据缺失),症状出现后采样时间常异质,最长至40天,所有时间点平均中位延迟5—6天。
  • 无抗体者与有抗体者年龄比较:WNV平均差-8·48岁(95% CI -12·31至-4·64),托斯卡纳病毒-6·97岁(-9·59至-4·35)。
  • 男性托斯卡纳病毒反应性OR 1·56(95% CI 1·15至2·11;p=0·0055);蚊虫叮咬WNV反应性OR 2·47(1·54至3·97;p=0·0002);蜱叮咬TBEV反应性OR 2·21(1·19至4·11;p=0·018)。

临床怎么用

  • 作者认为,尽管数据不完整且异质,疑似虫媒病毒感染的鉴别诊断仍可行,所提出的诊断判读算法或可用于加强虫媒病毒病风险地区临床环境中的常规诊断。
  • 原文未据此给出其他推荐。

局限性

  • 602例(70%)患者血清采样不完整(如一个或多个时间点样本缺失或症状出现时间数据缺失),影响血清学诊断虫媒病毒感染的能力。
  • 采样时间在症状出现后常异质,最长至40天,所有时间点平均中位延迟5—6天。
  • 部分个体临床数据不足,未能纳入临床分析,但符合纳入条件并纳入本分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Arboviruses are increasingly affecting Europe, partly due to the effects of climate change. This increase in range and impact emphasises the need to improve preparedness for emerging arboviral infections that often co-circulate and might have overlapping clinical syndromes. We aimed to strengthen surveillance networks for four clinically relevant arboviruses in southeast Europe. METHODS: This study reports an in-depth analysis of the MERMAIDS-ARBO prospective observational study in adults (ie, aged ≥18 years) hospitalised with an arbovirus-compatible disease syndrome in 21 hospitals in seven countries in southeast Europe over four arbovirus seasons (May 1-Oct 31, 2016-19) to obtain arbovirus prevalence outcomes. The main objectives of the MERMAIDS-ARBO study, describing the clinical management and outcomes of four arboviruses endemic to southeast Europe, including Crimean-Congo haemorrhagic fever virus (CCHFV), tick-borne encephalitis virus (TBEV), Toscana virus, and West Nile virus (WNV), are reported elsewhere. In this analysis, given the challenges associated with arbovirus diagnostics, we developed a diagnostic algorithm accounting for serology outcomes and sample timing to study arbovirus prevalence in southeast Europe. Serum samples were collected on days 0, 7, 28, and 60 after hospital admission and tested for anti-CCHFV IgG and IgM antibodies with ELISAs (confirmed with an indirect immunofluorescence test) and for IgG and IgM antibodies specific to TBEV, Toscana virus, and WNV with custom-printed protein microarrays (confirmed with virus neutralisation tests). All acute-phase samples were tested by PCR for all four viruses. Descriptive analyses were performed for virus-reactive cases by geography and year, and possible factors (eg, age, sex, and insect bites) associated with virus reactivity were assessed. FINDINGS: Of 2896 individuals screened, 913 were eligible for inclusion, of whom 863 (514 men, 332 women, and 17 unknown) had samples sent to the study reference laboratories and were included in molecular and serological analyses. Some individuals had insufficient clinical data to be included in the clinical analysis, but met the eligibility criteria for and were included here. Serum sampling was incomplete (eg, samples missing from one or more timepoints or no data on time since symptom onset) for 602 (70%) patients, and the timing of collection was often heterogeneous after symptom onset up to 40 days (average median delay of 5-6 days across all timepoints), affecting the ability to diagnose arbovirus infection by serology. By use of an interpretation table incorporating timing and completeness of sampling, one (<1%) participant had a confirmed recent infection with CCHFV, ten (1%) with TBEV, 40 (5%) with Toscana virus, and 52 (6%) with WNV. Most acute confirmed infections of Toscana virus were found in Albania (25 [63%] of 40), whereas WNV was primarily identified in Romania (36 [69%] of 52). Albania also had the highest overall Toscana virus seropositivity (168 [60%] of 282), mainly explained by patients confirmed to be exposed or previously exposed (104 [62%] of 168). Patients without antibodies to WNV or Toscana virus were significantly younger than patients with antibodies (mean difference -8·48 years [95% CI -12·31 to -4·64] for WNV, and -6·97 years [-9·59 to -4·35] for Toscana virus). We found higher odds of Toscana virus reactivity in men (odds ratio 1·56 [95% CI 1·15 to 2·11]; p=0·0055), WNV reactivity with mosquito bites versus no mosquito bites (2·47 [1·54 to 3·97]; p=0·0002), and TBEV reactivity with tick bites versus no tick bites (2·21 [1·19 to 4·11]; p=0·018). INTERPRETATION: This study shows that despite incomplete and heterogeneous data, differential diagnosis of suspected arbovirus infections is possible, and the diagnostic interpretation algorithm we propose could potentially be used to strengthen routine diagnostics in clinical settings in areas at risk for arboviral diseases. Our data highlight potential hotspots for arbovirus surveillance and risk factors associated with these particular arbovirus infections. FUNDING: European Commission and Versatile Emerging infectious disease Observatory. TRANSLATIONS: For the Greek, Albanian, Romanian, Bosnian, Serbian, and Croatian translation of the summary see Supplementary Materials section.

来源:Lancet Infect Dis,查看原文。版权归原作者所有。

引用

  1. Kasbergen LMR, de Bruin E, Chandler F, et al. Multi-antigen serology and a diagnostic algorithm for the detection of arbovirus infections as novel tools for arbovirus preparedness in southeast Europe (MERMAIDS-ARBO): a prospective observational study. Lancet Infect Dis. 2025. PMID: 39987930. doi:10.1016/S1473-3099(24)00654-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。